Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 15,500 GBp from 14,200 GBp and keeps a Buy rating on the shares, citing strong year-to-date performance, increased sales for Enhertu outside of the U.S. and Ultomiris, and SG&A leverage. The firm believes AstraZeneca, its preferred name among EU drugmakers for 2026, warrants a premium multiple to the group as “the most reliable growth story in EU Pharma” with potential for further catalyst-driven upside, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca price target raised to $103 from $93 at Morgan Stanley
- AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- AstraZeneca, GSK invited to help shape UK drug pricing regime, Sky News says